
A doctor shares 7 steps he'll review to decide when and where it's safe to go out and about
As we return to some degree of normalcy after weeks of social distancing, we all need a plan. As an immunologist, I’ve given this a lot of thought personally and professionally.
When I venture out, I am first going to check the number of . In Virginia, for example, as of May 16, some health districts had 200 new daily cases and others fewer than 10. I am going to be less risk-averse when new cases fall to near zero.
Second, I will assess my risk for severe infection and the risk for severe infection for those I will be visiting. The CDC defines these risk factors as being over age 65 or having serious underlying medical conditions, which include chronic lung disease, moderate to severe asthma, serious heart conditions, immunocompromise, severe obesity (body mass index over 40), diabetes, kidney disease requiring dialysis, liver disease or . If I have one of these risk factors, or am visiting someone with one of these risk factors, I am going to be extra-cautious.
Third, I will draw from knowledge about how COVID-19 is transmitted. Airborne transmission and fomites, or contaminated surfaces such as doorknobs, are . The SARS-CoV-2 virus that causes COVID-19 is stable in airborne droplets, or aerosols, for hours and on the surface of cardboard for a day and plastics for two days. A study in the New England Journal of Medicine, for example, showed that were without symptoms at the time of diagnosis, by nasal swab PCR test for the virus, and yet infectious to others. Normal speech generates but are captured by a cloth , preventing transmission to others.
I am going to wear a mask to help prevent my giving the infection to others, avoid touching surfaces such as handrails, try not to touch my eyes or nose or mouth with my hands and wash my hands frequently.
I am going to try to stay outdoors, where the risk of infection from aerosols is less, and if indoors stay six feet distant from others and limit my time there.
I am going to assess my risk for infecting others. If I have a fever, cough or other flu-like symptoms, such as muscle aches or tiredness, I am not going to venture out and risk exposing others to COVID-19. Even if healthy, I am going to wear a mask when out so that I can protect others if I am unknowingly infected but pre-symptomatic.
While it is tempting to resume normal activities, I have to remember – and I hope you will, too – that my individual behavior affects not only my health, but also yours.
This article is republished from under a Creative Commons license. Read the .
Image credit: Danielle Rice/UnsplashEnjoy reading 91ÑÇÉ«´«Ã½ Today?
Become a member to receive the print edition four times a year and the digital edition weekly.
Learn moreGet the latest from 91ÑÇÉ«´«Ã½ Today
Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.
Latest in Science
Science highlights or most popular articles

Meet Robert Helsley
The Journal of Lipid Research junior associate editor studies chronic liver disease and was the first in his family to attend college.

From the Journals: MCP
Protein acetylation helps plants adapt to light. Mapping protein locations in 3D tissues. Demystifying the glycan–protein interactome. Read about these recent papers.

Exploring life’s blueprint: Gene expression in development and evolution
Meet Julia Zeitlinger and David Arnosti — two co-chairs of the 91ÑÇÉ«´«Ã½â€™s 2025 meeting on gene expression, to be held June 26-29, in Kansas City, Missouri.

From the journals: JLR
Protein analysis of dopaminergic neurons. Predicting immunotherapy responses in lung cancer. ZASP: An efficient proteomics sample prep method. Read about papers on these topics recently published in Molecular & Cellular Proteomics.

New mass spectrometry assay speeds up UTI diagnosis
Scientists in Quebec use liquid chromatography–mass spectrometry to reduce the time needed to test for bacteria in urine from days to minutes — and with smaller samples.

From the journals: MCP
Protein analysis of dopaminergic neurons. Predicting immunotherapy responses in lung cancer. ZASP: An efficient proteomics sample prep method. Read about papers on these topics recently published in Molecular & Cellular Proteomics.